Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.86 UNCHANGED

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities

November 30, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More ↗

November 28, 2021

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week.

Via Talk Markets

The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week ↗

November 28, 2021

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses...

Via Benzinga

Takeda Celebrates World Quality Week

November 10, 2021

SOURCE: Takeda

Via 3BL Media

Earnings Scheduled For October 28, 2021 ↗

October 28, 2021

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •...

Via Benzinga

The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗

November 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...

Via Benzinga

Topics Intellectual Property

Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection ↗

November 24, 2021

The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after...

Via Benzinga

Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies

November 23, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug ↗

November 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...

Via Benzinga

The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...

Via Talk Markets

The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...

Via Benzinga

Monday Market Coverage ↗

November 15, 2021

Gold is up today on inflation fears.

Via Talk Markets

Takeda, Shattuck Labs Terminate Immuno-Oncology Pact ↗

November 09, 2021

Shattuck Labs Inc (NASDAQ: STTK) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) mutually agreed to terminate the Collaboration Agreement for SL-279252 and SL-115154...

Via Benzinga

Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease

November 04, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗

November 02, 2021

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...

Via Benzinga

Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website

November 01, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

No Negative Reaction ↗

October 28, 2021

Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today.

Via Talk Markets

Takeda's 1H Sales Increase 13%, Reaffirms FY21 Outlook, Announces Share Buyback ↗

October 28, 2021

Takeda Pharmaceutical Company Limited (NYSE: TAK) reported 1H FY21 sales of ¥1,794.4 billion, +12.8%. Underlying core revenue increased +6.8% Y/Y, driven by 14...

Via Benzinga

Takeda Announces Acquisition of Own Shares

October 28, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands

October 28, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors

October 27, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Wednesday Market Coverage ↗

October 20, 2021

Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.

Via Talk Markets

Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause ↗

October 20, 2021

Photo by MART PRODUCTION from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

Bitcoin Futures Arrive ↗

October 19, 2021

Today you can finally hold Bitcoins via an exchange-traded fund.

Via Talk Markets

The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗

October 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...

Via Benzinga

Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs ↗

October 19, 2021

Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue...

Via Benzinga

Calithera Buys Two Oncology Candidates From Takeda For $45M ↗

October 19, 2021

Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK)....

Via Benzinga

Chinese Growth Level ↗

October 18, 2021

The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.

Via Talk Markets

Europe's Unicorns ↗

October 15, 2021

After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.

Via Talk Markets

Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings ↗

October 15, 2021

Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings. Goldman rose 2.25% before the open helping to...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.